NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@article{Greenberg2011NCCNCP,
  title={NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.},
  author={P. Greenberg and E. Attar and J. Bennett and C. Bloomfield and C. D. De Castro and H. Deeg and J. Foran and K. Gaensler and G. Garcia-Manero and S. Gore and D. Head and R. Komrokji and L. Maness and M. Millenson and S. Nimer and M. O'donnell and M. Schroeder and P. Shami and R. Stone and James E. Thompson and P. Westervelt},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2011},
  volume={9 1},
  pages={
          30-56
        }
}
These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS… Expand
Update on the pharmacotherapy for myelodysplastic syndromes
New Treatments for Myelodysplastic Syndromes
Current treatment algorithm for the management of lower-risk MDS.
  • A. Giagounidis
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2017
Current and novel therapeutic approaches in myelodysplastic syndromes.
Managing myelodysplastic syndromes in very old patients: a teaching case report
Treatment of low-risk myelodysplastic syndromes.
  • V. Santini
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2016
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Treatment of myelodysplastic syndromes.
Management of patients with higher risk myelodysplastic syndromes.
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
  • S. Nimer
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
  • D. Oliansky, J. Antin, +10 authors T. Hahn
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2009
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
...
1
2
3
4
5
...